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Purpose: Teriparatide markedly increases bone formation and strength, while re-
ducing the incidence of new-onset osteoporotic vertebral compression fractures 
(OVCFs). In some countries, expenses for teriparatide use are covered by medical 
insurance for up to 6 months; however, the national medical insurance of the au-
thors’ country does not cover these expenses. This retrospective cohort study com-
pared the therapeutic effects of teriparatide on the initial onset of a new OVCF af-
ter treatment of osteoporosis and/or related OVCFs with regard to therapeutic 
durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). Ma-
terials and Methods: From May 2007 to February 2012, 404 patients who were 
prescribed and administered teriparatide and who could be followed-up for longer 
than 12 months were enrolled. They were divided into two groups depending on 
teriparatide duration: LT3M (n=132) and ST3M (n=272). Results: The group with 
the teriparatide duration of LT3M showed significantly less development of an ini-
tial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body 
mass index, pre-teriparatide lowest spinal bone mineral density, and severity of os-
teoporosis significantly affected multiple regression analysis results (p<0.05). Sur-
vival analysis of first new-onset OVCFs demonstrated a significantly better surviv-
al rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a 
higher odds ratio of 54.00 for development of an initial OVCF during follow-up 
than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). Conclusion: 
At least one cyclic teriparatide administration is recommended to provide a protec-
tive effect against the initial onset of a new OVCF for up to one year after therapy.
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INTRODUCTION
Osteoporotic vertebral compression fractures (OVCFs) are the most common fra-
gility fracture and are a hallmark of osteoporosis. OVCFs are associated with sig-
nificantly decreased quality of life and increased mortality in the elderly.1,2 Nowa-
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teriparatide administration [20 mcg/day, 250 mcg/mL×2.4 
mL for 1 pen (28 days duration), Lilly Korea] were collect-
ed from electronic medical records. 
In all enrolled patients, dual energy X-ray absorptiometry 
was performed using a GE-lunar densitometer (Lunar Prod-
igy, GE Lunar Corp., Madison, WI, USA). This technique 
was used to measure areal bone mineral density (BMD) of 
the lumbar spine previous to teriparatide administration, and 
measurements were repeated annually. An established visu-
al semi-quantitative system was used to evaluate the pres-
ence of OVCFs12 on conventional thoraco-lumbar lateral 
radiographs taken at regular follow-up visits on a monthly 
basis for up to 3 months after first prescription of teripara-
tide. Then, patients were allowed to visit freely when they 
consumed all the osteoporosis medication or newly devel-
oped back pain was detected. To confirm a new onset OVCF, 
magnetic resonance imaging was performed in patients with 
new onset back pain and/or a new suspected OVCF on fol-
low-up lateral plain radiographs during follow-up. 
Enrolled patients were divided into two groups based on 
teriparatide duration: shorter than 3 months (ST3M) or lon-
ger than 3 months (LT3M). Basic data were compared be-
tween the two groups (Table 1). Co-existing degenerative 
spine conditions consisted of spinal stenosis (118 patients), 
spinal stenosis with spondylolisthesis (27 patients), degener-
ative scoliosis (29 patients), and herniated nucleus pulposus 
(25 patients).
Statistical analysis 
An independent t-test was used to compare the results be-
tween groups. Chi-square test was conducted to analyze the 
distribution of initial OVCFs depending on duration of terip-
aratide use. Mantel-Haenzel common odds ratio analysis 
was used to estimate the odds ratio of the development of a 
new OVCF between the two groups. Forward stepwise mul-
tiple regression analyses were used to investigate factors af-
fecting the development of the initial OVCFs, including age, 
gender, severity of osteoporosis, duration of teriparatide ad-
ministration, previous history of vertebroplasty (VP), low-
est femoral BMD score before teriparatide administration, 
lowest spine BMD score before teriparatide administration, 
presence of pre-existing OVCFs, body mass index (BMI), 
types and duration of pre-teriparatide and post-teriparatide 
osteoporosis medications, and co-morbidities. Kaplan-Mei-
er survival analysis and a log-rank test were used to com-
pare initial OVCF development between the ST3M and 
LT3M groups. Additional statistical analyses including chi-
days, multi-disciplinary approaches to prevent OVCFs, 
including prevention of falls and administration of osteopo-
rosis medications, are mandatory.3,4 Among different osteo-
porosis medications, teriparatide was the first anabolic agent 
approved by the U.S Food and Drug Administration to treat 
osteoporosis.5 Teriparatide involves a direct mechanism that 
stimulates bone formation and improves bone strength fast-
er than other anti-resorptive osteoporosis medications.4,6-9 
The dramatic bone formation seen with teriparatide ther-
apy peaks at 6 to 12 months of therapy.10 However, the high 
price of teriparatide therapy (800 US dollars/month), rough-
ly 30-fold higher than weekly bisphosphonate for a month, 
sometimes hampers its continuous use in clinical settings. 
Moreover, studies have yet to suggest clinical guidelines for 
preventing new OVCFs in patients using teriparatide, in 
particular how long teriparatide should be administered to 
ensure protective effects against the development of new-
onset OVCFs.
In the present study, we investigated the minimum period 
of teriparatide use necessary to ensure prevention of addi-
tional new-onset OVCFs. Additional correlation analyses 
were also conducted to determine the initial onset of a new 
OVCF after teriparatide treatment in a clinical setting ac-
cording to duration of teriparatide administration. 
MATERIALS AND METHODS
This study was approved by the Institutional Review Board 
of the authors’ hospital (IRB No. 3-2012-0221). 
From May 2007 to February 2012, 650 patients were pre-
scribed and administered teriparatide for at least 1 month for 
treatment of osteoporosis and/or OVCFs as suggested by 
guidelines for osteoporosis treatment.3,11 Among these, 430 
patients who were followed-up for longer than 12 months 
were enrolled in the present study. 
Additionally, data from patients who met the following 
exclusion criteria were removed from analysis: 1) musculo-
skeletal conditions that altered bone condition, such as ar-
throgryposis multiplex congenita, neuromuscular scoliosis, 
and Down syndrome; 2) patients who had a new onset 
OVCF from major trauma, such as a fall from a height or 
traffic accidents during follow-up; and 3) patients in whom 
complications related to teriparatide use were detected, such 
as generalized weakness and hypercalcemia. 
A total of 26 patients were excluded from the patient pool, 
and 404 patients were finally enrolled. Basic data related to 
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mg/dL of inorganic phosphate (normal range 2.8‒4.5), and 
34.15±19.0 ng/mL of 25-OH vitamin D3. 
The 1-year post-teriparatide follow-up lab analysis re-
vealed 76.8±22.3 ng/dL of T3, 4.6±3.7 mcg/dL of T4, 0.54± 
0.55 ng/mL of CTX, 43.1±22.7 ng/mL of OC, 25.8±14.1 pg/
mL of PTH, 78.0±34.1 nM BCE/nM Cr of NTX, 9.0±1.4 
mg/dL of calcium, 3.6±0.5 mg/dL of inorganic phosphate, 
and 36.7±11.2 ng/mL of 25-OH vitamin D. 
From a total of 404 patients, 272 (67.3%) patients were 
categorized in the ST3M group and 132 (32.7%) patients in 
LT3M group. Table 1 shows a comparison between ST3M 
and LT3M groups. Among many factors, only the duration 
of teriparatide use was significantly different between the 
two groups (p=0.000, independent t-test). 
A total of 17 (4.2%) patients exhibited an initial OVCF dur-
ing follow-up. There was no difference in the overall develop-
ment of an initial OVCF between ST3M (10 cases among 
272 cases, 3.7%) and LT3M (seven cases among 132 cases, 
5.3%) groups. However, there was a significantly different 
distribution of initial OVCFs within 1 year, which developed 
less in the LT3M group (one of seven first new OVCFs) than 
the ST3M group (nine of 10 first new OVCFs) (p=0.004, 
chi-square) (Fig. 1). 
Pre- and post-teriparatide osteoporosis medication 
Prior to teriparatide administration, only 102 patients (25.2%) 
had been treated for osteoporosis and were taking calcium-
vitamin D supplements (31 patients) or bisphosphonate (71 
patients). The mean duration of taking calcium-vitamin D 
supplements was 3.7±6.5 months. The mean duration of 
square and survival analyses were also performed to inves-
tigate the effect of VP status and preexisting OVCFs status 
on the development of an initial OVCF. All statistical anal-
yses were performed using the SPSS 12.0.1 statistics pack-
age (SPSS Inc., Chicago, IL, USA). p-values <0.05 were 
considered statistically significant. 
 
RESULTS
 
The mean age of enrolled patients was 72.5 years (50‒91 
years). Four hundred and four postmenopausal females 
were enrolled. The mean follow-up period was 27.0±13.9 
months (12‒57 months).
Before teriparatide use, the lowest spine BMD was -3.1± 
1.2 and the lowest femoral BMD, other than the femoral 
Ward’s triangle, was -2.5±1.0. The mean duration teripara-
tide was 3.3±2.8 months. Mean BMI was 22.5±3.5. The 
mean number of co-morbidities was 1.9±0.9. Mean onset 
of an initial OVCF was 13.3±12.8 months after the first 
teriparatide administration.
The mean results of pre-teriparatide serologic tests were 
93.9±29.1 ng/dL of T3 (normal range 71‒161), 6.21±3.54 
mcg/dL of T4 (normal range 5.5‒10.6), 0.52±0.34 ng/mL 
of C-terminal telopeptide (CTX) (normal range 0.11‒1.00), 
27.4±27.2 ng/mL of osteocalcin (OC) (normal range 8.0‒ 
44.0), 44.5±25.2 pg/mL of intact parathyroid hormone 
(PTH) (normal range 13‒104), 56.9±36.0 nM BCE/nM Cr 
of N-terminal telopeptide (NTX) (normal range 6.0‒125.72), 
8.7±0.6 mg/dL of calcium (normal range 8.6‒10.0), 3.6±0.9 
Table 1. Comparison of Results Depending on Duration of Teriparatide Use 
LT3M (n=132) ST3M (n=272) p value
Age 71.4±9.9 72.9±8.3 NS
Osteopenia: osteoporosis: severe osteoporosis (<-3.0) 38:28:66 77:36:159 NS
Pre-teriparatide bisphosphonate use (+):(-)* 24:108 47:225 NS
Pre-teriparatide spinal bone densitometry  -2.9±1.2  -3.1±1.2 NS
Post-teriparatide bisphosphonate use (+):(-)* 63:69 99:173 0.031
Post-teriparatide spinal bone densitometry at 1 yr F/U  -2.6±1.3  -2.7±1.0 NS
Vertebroplasty status (+):(-)* 18:114 78:194 0.001
Co-morbidity   2.0±0.9   1.8±0.9 NS
Pre-existing OVCF (+):(-)* 61:71 156:116 0.033
BMI (kg/m2) 23.2±3.6 22.4±3.5 NS
Teriparatide duration (months)   6.7±2.5   1.7±0.8 0.000
Onset of an initial OVCF (months)   23.7±12.4   6.0±6.9 0.007
LT3M, longer than 3 months; ST3M, shorter than 3 months; BMI, body mass index; OVCF, osteoporotic vertebral compression fracture; F/U, follow-up; NS, 
not significant. 
Independent t-test and Mann-Whitney U test were used to compare means of the two groups.
*Chi-square test was used.
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group showed an even distribution of initial OVCFs (11 
cases) during follow-up. The preexisting OVCF (-) group 
recorded one out of six cases at 3 month follow-up and oth-
er five cases after 24 months of follow-up. 
The VP (+) group and VP (-) group showed statistically 
different survival rates (log rank, p=0.000) (Fig. 4). All new 
OVCFs in 8 cases in the previous VP (+) group occurred 
within 1 year during follow-up. The previous VP (-) group 
showed an even distribution of nine initial OVCFs during 
bisphosphonate medication was 11.9±17.6 months. 
After teriparatide administration, 249 patients (61.6%) 
taking calcium-vitamin D supplements (87 patients) or 
bisphosphonate (162 patients) were treated for osteoporosis. 
The mean duration of taking calcium-vitamin D supple-
ments during follow-up was 4.0±4.4 months. The mean du-
ration of bisphosphonate medication after teriparatide ad-
ministration was 11.7±9.8 months. There was no difference 
in type and duration of pre-teriparatide osteoporosis medi-
cation between initial OVCF (+) and initial OVCF (-) pa-
tients during follow-up.
Osteopenia/osteoporosis/severe osteoporosis (<-3.0)
Two of (1.7%) 115 cases of osteopenia, two of (3.1%) 64 
cases of osteoporosis, and 14 (6.2%) of 225 cases of severe 
osteoporosis (<-3.0) were confirmed to have an initial OVCF 
during follow-up. There was no statistical difference in the 
development of an initial OVCF between osteopenia, os-
teoporosis, and severe osteoporosis groups.
Preexisting OVCFs status 
Among 404 patients, 217 (53.7%) patients had preexisting 
OVCFs and 183 (45.3%) patients did not. Six cases of an 
initial OVCF were detected among preexisting OVCFs (-) 
patients and 11 cases of an initial OVCF were detected in 
preexisting OVCFs (+) patients. There was no statistical 
difference according to preexisting OVCFs status. 
Vertebroplasty status
Ninety-six (23.8%) patients underwent VP before teripara-
tide administration. Depending on VP status, a significant 
difference in the development of an initial OVCF was detect-
ed. Nine (2.9%) of 314 non-VP patients and eight (8.9%) of 
90 VP patients showed an initial OVCF (p=0.027, chi-
square). Among VP patients, adjacent OVCFs were observed 
in four (50%) cases, while all others were distant OVCFs. 
Survival analysis 
Survival analysis of a first new onset OVCF showed a sta-
tistical difference in the survival rates of both groups (log 
rank, p=0.005) (Fig. 2).
In the LT3M group, only one of 7 patients developed an 
initial OVCF within 12 months. In the ST3M group, most 
(nine of 10) initial OVCFs occurred within 1 year (Fig. 2).
There was a statistical difference between the survival 
rates depending on preexisting OVCFs (+) and (-) status 
(log rank, p=0.005) (Fig. 3). The preexisting OVCF (+) 
Fig. 1. Distribution of an initial OVCF depending on teriparatide duration. 
The group with teriparatide duration of LT3M exhibited a statistically differ-
ent distribution pattern of initial OVCFs within 1 year, compared to that of 
the group with teriparatide duration of ST3M (p=0.004, chi-square). The 
mean onset time of an initial OVCF was 23.7±12.4 months in the LT3M group 
and 6.0±6.9 months in the ST3M group (Mann-Whitney U test, p=0.007). 
Also, the ST3M group showed higher odds ratio of 54.000 (95% confidence 
interval: 2.804−1040.048) for the development of an initial OVCF during fol-
low-up than the LT3M group (Mantel-Haenzel common odds ratio esti-
mates, p=0.006). OVCFs, osteoporotic vertebral compression fractures; 
LT3M, longer than 3 months; ST3M, shorter than 3 months.
Fig. 2. Survival analysis of an initial OVCF depending on teriparatide duration. 
We observed a statistically significant difference in the occurrence of an ini-
tial OVCF between groups, which was better in the teriparatide duration of 
LT3M group (log rank, p=0.005). In the LT3M group, only one of 7 patients de-
veloped an initial OVCF within 12 months. In the ST3M group, most (9 of 10) 
initial OVCFs occurred within 1 year. OVCFs, osteoporotic vertebral compres-
sion fractures; LT3M, longer than 3 months; ST3M, shorter than 3 months.
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analysis of clinical trials, patients treated with teriparatide 
exhibited a reduced incidence of back pain and also an in-
creased quality of life relative to patients receiving a place-
bo and anti-resorptive drugs.15-17
One major concern with teriparatide is its high price. Be-
cause teriparatide costs more than 800 US dollars per month 
in the authors’ country, it is not uncommon to meet patients 
who insist on changing to other osteoporosis medications, 
such as bisphosphonate, which costs roughly 30 US dollars 
per month. In some countries, expenses for teriparatide use 
are covered by medical insurance for up to 6 months; how-
ever, the national medical insurance of the authors’ country 
does not cover these expenses. To reflect this clinical back-
ground, in the present study, only 32.7% of enrolled patients 
were administered teriparatide for longer than 3 months. 
Different from the clinical setting of the present study, 
many clinical results have been determined based on long-
term teriparatide use for 12 to 24 months.8,10 Even short-term 
treatment with teriparatide was proven effective at increasing 
cancellous, endocortical, and periosteal bone formation 
rates.18 In a teriparatide fracture prevention trial, teriparatide 
reduced the risk of new vertebral fractures and nonvertebral 
24 months of follow-up. 
In multiple regression analysis, test results were signifi-
cantly affected by duration of teriparatide use, BMI, lowest 
pre-teriparatide spine BMD, and severity of osteoporosis (p< 
0.05) (Table 2). Age, pre-existing OVCFs, VP status, low-
est pre-teriparatide femoral BMD, types and duration of 
pre-teriparatide and post-teriparatide osteoporosis medica-
tion, pre- and post-teriparatide bisphosphonate medication 
and co-morbidity did not affect the development of a first 
new OVCF.
Also, the ST3M group showed higher odds ratio of 54.000 
(95% confidence interval: 2.804‒1040.048) for development 
of an initial OVCF during follow-up than the LT3M group 
(Mantel-Haenzel common odds ratio estimates, p=0.006).
DISCUSSION
Subcutaneous teriparatide injection was previously shown 
to be associated with increased trabecular bone, cortical pa-
rameters, bone formation rates, and successive fracture pre-
vention to reduce fracture risk.5,8,13,14 In a published meta-
Table 2. Multiple Pegression Analysis of Factors Related to Development of an Initial OVCF
Factors β±standard error p value
Teriparatide duration -0.060±0.017 0.001
Body mass index -0.042±0.012 0.001
Pre-teriparatide lowest spinal BMD -0.122±0.045 0.009
Osteopenia/osteoporosis/severe osteoporosis (<-3.0)  0.097±0.038 0.013
OVCF, osteoporotic vertebral compression fracture; BMD, bone mineral densitometry.
Fig. 3. Survival analysis of an initial OVCF depending on the presence of 
preexisting OVCFs. The occurrence of an initial OVCF in the preexisting 
OVCF (+) group was statistically different from those of the preexisting 
OVCF (-) group (log rank, p=0.005). The preexisting OVCF (+) group showed 
an even distribution of initial OVCFs (11 cases) during follow-up. The preex-
isting OVCF (-) group recorded one case out of six cases at 3 month follow-
up and another five cases after 24 months of follow-up. OVCFs, osteoporot-
ic vertebral compression fractures.
Fig. 4. Survival analysis of an initial OVCF depending on VP status. There 
was a significantly different survival rate for the previous VP (+) group and 
VP (-) group (log rank, p=0.000). All initial OVCFs in eight cases in the previ-
ous VP (+) group occurred within 1 year during follow-up. The previous VP 
(-) group showed an even distribution of nine initial OVCFs during 24 
months of follow-up. OVCFs, osteoporotic vertebral compression fractures; 
VP, vertebroplasty.
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related to previous bisphosphonate medication use. 
The present study also confirmed the possible detrimental 
effects of presence of preexisting OVCFs and VP status dur-
ing teriparatide use. Sagittal imbalance of the whole spine 
caused by preexisting OVCFs could contribute to the dif-
ferent distributions of development of an initial OVCF due 
to biomechanical uneven axial loading on adjacent verte-
brae (Fig. 3), as a fully restored augmented vertebral body 
with appropriate sagittal alignment would be the goal of 
treatment.21,22 Although teriparatide improves bone strength 
faster than other anti-resorptive agents,7,8,23,24 all first new 
OVCFs developed within 1 year in VP patients (Fig. 4). Pa-
tients who undergo VP have been reported to have a greater 
risk of new-onset OVCFs in adjacent and non-adjacent spi-
nal levels, compared to patients with prior OVCFs who did 
not undergo VP,25,26 which supports recent studies that have 
questioned the effects of VP.7,26-31 Therefore, VP status and 
presence of preexisting OVCFs also must be closely moni-
tored in patients administered teriparatide to prevent new 
onset OVCFs. 
In addition, multiple regression analysis in the present 
study also showed that BMI, severity of osteoporosis, and 
low BMD affect the development of initial OVCFs with 
teriparatide use correspondent to previous studies.32-34 Also, 
considering pre- and posterior teriparatide as factors affect-
ing the development of initial OVCFs, the authors showed 
that short term use of bisphosphonate and calcium-vitamin 
D supplements did not affect the development of initial 
OVCFs. Therefore, this would support a stronger effect for 
teriparatide, compared to a long duration of bisphosphonate 
use, even with a mean duration of 6.7 months in the LT3M 
group, with 11.9 months of pre-teriparatide and 11.7 months 
of post-teriparatide use.
Limitations of the present study include lack of a pain 
scale during follow-up due to the retrospective study design 
and a failure to control possible confounding factors, such as 
pre-teriparatide and/or post-teriparatide osteoporosis medi-
cation. Nevertheless, the major finding of this study sug-
gests that at least 3 months of teriparatide use should be the 
new standard in patients with high fracture risk or intoler-
ance to other osteoporosis therapies.35 Also, the present au-
thors focused on the development of an initial OVCF in-
stead of development of all OVCFs during follow-up. 
In conclusion, at least 3 months of cyclic teriparatide use 
was associated with lower risk and delayed onset time for 
an initial OVCF after treatment during follow-up. At least 3 
months of continuous teriparatide administration is suggest-
fractures, but unfortunately, the study was stopped early be-
cause of the discovery of increased risk of osteosarcoma in 
animal models.5,8
One purpose of the present study was to investigate how 
long physicians should recommend candidates for such an 
expensive and possibly osteosarcoma-related medication to 
prevent new OVCFs. As expected, 3 months of teriparatide 
use, which the authors considered compatible with the nor-
mal physiologic bone cycle,19,20 showed a different pattern 
of initial OVCF development. Nevertheless, the authors 
failed to show a reduction in the total incidence of initial 
OVCFs for the LT3M group, compared to the ST3M group. 
However, the LT3M group demonstrated at least the delay-
ing of or protective effects of teriparatide on the develop-
ment of initial OVCFs in terms of recovering and strength-
ening bone quality in osteoporotic patients (Fig. 1). Paying 
closer attention to the interpretation of Fig. 1, the authors 
did not attempt to show an increase in the development of 
new OVCFs in the LT3M group after 1 year, but rather want-
ed to demonstrate the delaying effect of teriparatide on the 
development of an initial OVCF after treatment between 
the two groups. The mean new OVCFs free periods were 
four times longer in the LT3M group than in the ST3M 
group (Table1). Finally, the longer period free from a new 
OVCF in the LT3M group would translate to greater cost-
effectiveness in clinical settings, reducing OVCF-related 
social-economic burdens stemming from the use of teripa-
ratide, compared with other osteoporosis medications.21,22  
Additionally, we confirmed a higher odds ratio for the de-
velopment of an initial OVCF within 1 year in the ST3M 
group than the LT3M group. Therefore, the present authors 
highly encourage the use of teriparatide for longer than 3 
months. 
As for compliance of teriparatide administration, interest-
ingly, because teriparatide is expensive, most of the patients 
that underwent daily teriparatide self-injection did not want 
to miss a single dose for 1 month. Also, post-teriparatide 
osteoporosis treatment ratio increased. 
In the present study, pre-teriparatide osteoporosis medi-
cation use was a major confounding factor, which could 
have affected the development of initial OVCFs. Unfortu-
nately for patients, the administration of osteoporosis medi-
cations prior to teriparatide therapy was very low (25.2% 
only), and the ratio of taking bisphosphonate, which is a 
stronger confounding factor than calcium-vitamin D sup-
plements, was only 17% among enrolled patients. There-
fore, the authors could easily exclude confounding effects 
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